Important Milestone Toward Bringing SSO 2 Therapy to the U.S. Market Simon Dixon, MBChB, chair of cardiovascular medicine at Beaumont Hospital Royal Oak and an investigator for this study, noted, “In ...
CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO 2) Therapy, which delivers high levels of dissolved oxygen directly to the ...
CHELMSFORD, Mass., October 31, 2022--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated ...
One small med-tech firm is developing a system that is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart ...
ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination ...
American Medical Association Issues New Category III CPT Code for ZOLL Medical’s TherOx SSO2 Therapy
The Category III CPT code for SSO 2 Therapy was supported by the leadership of the Society for Cardiac Angiography and Interventions (SCAI) and the American College of Cardiology (ACC). The decision ...
TherOx Inc., an Irvine-based medical device maker, said last week it raised $30 million in financing. The money will help pay for a clinical study of its therapeutic oxygen system used to help treat ...
SAN DIEGO - A physician at Scripps Health's Prebys Cardiovascular Institute has become the first in the Western United States to treat heart attack patients with a new supersaturated oxygen (SSO2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results